Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Can J Physiol Pharmacol ; 94(6): 634-42, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27050838

RESUMEN

Myocardial infarction (MI) has been associated with an inflammatory response and a rise in TNF-α, interleukin (IL)-1ß, and IL-6. Peroxisome proliferator-activated receptors (PPARs) promote a decreased expression of inflammatory molecules. We aimed to study whether PPAR stimulation by clofibrate decreases inflammation and reduces infarct size in rats with MI. Male Wistar rats were randomized into 3 groups: control, MI + vehicle, and MI + clofibrate (100 mg/kg). Treatment was administered for 3 consecutive days, previous to 2 h of MI. MI induced an increase in protein expression, mRNA content, and enzymatic activity of inducible nitric oxide synthase (iNOS). Additionally, MI incited an increased expression of matrix metalloproteinase (MMP)-2 and MMP-9, intercellular adhesion molecule (ICAM)-1, and IL-6. MI also elevated the nuclear content of nuclear factor-κB (NF-κB) and decreased IκB, both in myocyte nuclei and cytosol. Clofibrate treatment prevented MI-induced changes in iNOS, MMP-2 and MMP-9, ICAM-1, IL-6, NF-κB, and IκB. Infarct size was smaller in clofibrate-treated rats compared to MI-vehicle animals. In silico analysis exhibited 3 motifs shared by genes from renin-angiotensin system, PPARα, iNOS, MMP-2 and MMP-9, ICAM-1, and VCAM-1, suggesting a cross regulation. In conclusion, PPARα-stimulation prevents overexpression of pro-inflammatory molecules and preserves viability in an experimental model of acute MI.


Asunto(s)
Modelos Animales de Enfermedad , Regulación hacia Abajo/fisiología , Mediadores de Inflamación/metabolismo , Infarto del Miocardio/metabolismo , PPAR alfa/biosíntesis , Animales , Clofibrato/farmacología , Clofibrato/uso terapéutico , Regulación de la Expresión Génica , Masculino , Infarto del Miocardio/tratamiento farmacológico , PPAR alfa/genética , Distribución Aleatoria , Ratas , Ratas Wistar
2.
Nat Med ; 17(1): 117-22, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21151138

RESUMEN

The main manifestations of nephrotic syndrome include proteinuria, hypoalbuminemia, edema, hyperlipidemia and lipiduria. Common causes of nephrotic syndrome are diabetic nephropathy, minimal change disease (MCD), focal and segmental glomerulosclerosis (FSGS) and membranous nephropathy. Among the primary glomerular diseases, MCD is usually sensitive to glucocorticoid treatment, whereas the other diseases show variable responses. Despite the identification of key structural proteins in the glomerular capillary loop which may contribute to defects in ultrafiltration, many of the disease mechanisms of nephrotic syndrome remain unresolved. In this study, we show that the glomerular expression of angiopoietin-like-4 (Angptl4), a secreted glycoprotein, is glucocorticoid sensitive and is highly upregulated in the serum and in podocytes in experimental models of MCD and in the human disease. Podocyte-specific transgenic overexpression of Angptl4 (NPHS2-Angptl4) in rats induced nephrotic-range, and selective, proteinuria (over 500-fold increase in albuminuria), loss of glomerular basement membrane (GBM) charge and foot process effacement, whereas transgenic expression specifically in the adipose tissue (aP2-Angptl4) resulted in increased circulating Angptl4, but no proteinuria. Angptl4(-/-) mice that were injected with lipopolysaccharide (LPS) or nephritogenic antisera developed markedly less proteinuria than did control mice. Angptl4 secreted from podocytes in some forms of nephrotic syndrome lacks normal sialylation. When we fed the sialic acid precursor N-acetyl-D-mannosamine (ManNAc) to NPHS2-Angptl4 transgenic rats it increased the sialylation of Angptl4 and decreased albuminuria by more than 40%. These results suggest that podocyte-secreted Angptl4 has a key role in nephrotic syndrome.


Asunto(s)
Angiopoyetinas/genética , Síndrome Nefrótico/orina , Proteinuria/prevención & control , Albuminuria/prevención & control , Proteína 4 Similar a la Angiopoyetina , Angiopoyetinas/metabolismo , Animales , Modelos Animales de Enfermedad , Humanos , Ratones , Ratones Noqueados , Síndrome Nefrótico/fisiopatología , Proteinuria/genética , Ratas , Ratas Transgénicas
3.
Int Arch Allergy Immunol ; 130(3): 232-5, 2003 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12660428

RESUMEN

BACKGROUND: The best example of a chronic inflammatory respiratory disease is asthma, a disease which has an increasing prevalence worldwide. This chronic inflammation is also related to the generation of oxidative stress since the cells involved in the allergic reaction are capable of producing reactive oxygen species (ROS), and this might predispose asthmatics to increased genotoxic damage. METHODS: A respiratory symptomatology questionnaire was self-applied by asthmatic and nonasthmatic students. A single cell gel electrophoresis assay in two different cell types (nasal epithelial cells and leukocytes) was performed, and the cytology of the nasal smears stained with HE was evaluated. RESULTS: Both groups reported having a runny nose. Asthmatics had greater DNA damage in the nasal epithelial cells in contrast to nonasthmatics. In leukocytes no statistical significance in DNA damage was identified. Metaplasia was evident in asthmatics that also showed eosinophils and neutrophils as well as goblet cells and mucus at a higher frequency compared with nonasthmatics. CONCLUSIONS: Nasal symptoms did not correlate with genotoxic damage, since they were reported in both groups. Nasal epithelial cells of asthmatics are more sensitive to genotoxic damage, and chronic inflammatory response. Also the activity of eosinophils might mediate the DNA damage through the generation of ROS.


Asunto(s)
Asma/genética , Asma/patología , Daño del ADN , Leucocitos/metabolismo , Mucosa Nasal/patología , Adulto , Contaminación del Aire/efectos adversos , Asma/metabolismo , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Mucosa Nasal/metabolismo , Especies Reactivas de Oxígeno/metabolismo
4.
La Paz; s.n; sept. 2005. [5] p.
No convencional en Español | LIBOCS, LIBOSP | ID: biblio-1301390
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA